WO2023105528A1 - Anticorps spécifiques de ceacam1 - Google Patents

Anticorps spécifiques de ceacam1 Download PDF

Info

Publication number
WO2023105528A1
WO2023105528A1 PCT/IL2022/051305 IL2022051305W WO2023105528A1 WO 2023105528 A1 WO2023105528 A1 WO 2023105528A1 IL 2022051305 W IL2022051305 W IL 2022051305W WO 2023105528 A1 WO2023105528 A1 WO 2023105528A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cancer
seq
sequence
ceacam1
Prior art date
Application number
PCT/IL2022/051305
Other languages
English (en)
Inventor
Francesca Levi-Schaffer
Stipan Jonjic
Ilan ZAFFRAN
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
University Of Rijeka Faculty Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd., University Of Rijeka Faculty Of Medicine filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Publication of WO2023105528A1 publication Critical patent/WO2023105528A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the invention is in the field of immunotherapy and relates to antibodies and fragments thereof which bind to the protein carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1, CD66a), to polynucleotide sequences encoding these antibodies and antibody fragments and to cells producing them.
  • CEACAM1, CD66a protein carcinoembryonic antigen-related cell adhesion molecule 1
  • the invention further relates to therapeutic and diagnostic compositions comprising these antibodies and fragments and to methods of treating and diagnosing diseases, particularly cancer, using them.
  • Cancer immunotherapy is one of the most promising advancements made in the past decade.
  • Four main approaches are being used to harness immune cells to fight cancer: 1) antibodies directed against tumor antigens are injected into patients and tumors are eliminated, in part, by immune cells carrying Fc receptors that recognize the antibody-coated tumors; 2) anti-cancer immune cells are extracted from the patient, expanded in vitro (and sometimes even genetically manipulated), and then re-injected into the patient; 3) T cells engineered to express Chimeric Antigen Receptors (CAR) that recognize tumor antigens are injected into patients; and 4) activity of the immune cells is augmented by using mAbs that block inhibitory pathways (known as checkpoints) that operate to restrain the immune cells.
  • CAR Chimeric Antigen Receptors
  • CEACAM1 The transmembrane protein carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1, also known as biliary glycoprotein, BGP, CD66a and C-CAM1), is a member of the carcinoembryonic antigen (CEA) family that belongs to the immunoglobulin superfamily.
  • CEACAM1 has been assigned the SwissProt accession number P13688.
  • CEACAM1 interacts with itself and with other known CEACAM proteins, including the subtypes CD66c (CEACAM6) and CD66e (CEACAM5, CEA).
  • Human CEACAM1 is expressed on a wide spectrum of cells, ranging from epithelial cells to those of hemopoietic origin (e.g. immune cells), including many cancer cells.
  • CEACAM1 has been attributed to many different functions. It was shown that the CEACAM1 protein is over expressed in some carcinomas of colon, prostate, as well as other types of cancer, such as melanoma. Additional data support the central involvement of CEACAM1 in angiogenesis and metastasis. CEACAM1 also plays a role in the modulation of innate and adaptive immune responses. For example, CEACAM1 was shown to be an inhibitory receptor for activated T cells contained within the human intestinal epithelium (WO 99/52552 and Morales et al. J. Immunol. 1999, 163, 1363-1370).
  • CEACAM1 engagement either by T cell receptor cross-linking with monoclonal antibodies (mAbs) or by Neisseria gonorrhea Opa proteins inhibits T cell activation and proliferation.
  • monoclonal antibodies mAbs
  • Neisseria gonorrhea Opa proteins inhibit T cell activation and proliferation.
  • monoclonal antibodies against the CEACAM1 protein are already known and some of them are tested in clinical trials.
  • WO 2015/166484 discloses humanized antibody against CEACAM1, useful for preventing, attenuating or treating a disease associated with expression, activation or function of a CEACAM1 protein.
  • tumors express CEACAM1, an inhibitory molecule that can potentially inhibits tumor proliferation. It is possible that tumors express CEACAM1 to inhibit the activity of CEACAM1 -positive immune cells. Since CEACAM1 also function as adhesion molecule, it is possible that tumors express it to enhance tumor motility and metastases. It is also possible that in the initial stages of tumor development inhibition of tumor growth is required for the tumor to properly establish itself in the tumor niche. Regardless, the fact that different tumors express CEACAM1 provide an opportunity to target these tumors by developing antibodies specific to protein.
  • the present invention provides according to some embodiments, antibodies and fragments thereof that recognize the protein CEACAM1 (CD66a).
  • the anti-CEACAMl antibodies disclosed herein are capable of binding to CEACAM1 present on cancer cells and to induce their killing.
  • the antibodies of the present invention are agonistic/activating antibodies that do not bind the N-terminal domain of CEACAM1 and therefore are not involved in interactions mediated through this domain of the protein. This unique characteristic of the antibodies of the present invention confers them with enhances safety as inhibition of homophilic interactions of CEACAM1 through its N-terminal may lead in some circumstances to tumor proliferation.
  • CDR complementarity determining region
  • anti-CEACAMl antibodies described herein were found to reduce tumor cell viability in an immune independent manner, to induce killing of melanoma cells in vitro and reduce tumor size and weight in xenograft in vivo model in dose-dependent manner.
  • the anti-CEACAMl antibodies of the present invention were also able to stain CEACAM1 on eosinophils of COVID-19 infected patients.
  • the present invention provides an antibody, or an antibody fragment thereof comprising at least the antigen binding portion, which specifically binds to CEACAM1, said antibodies do not block CEACAM1 homophilic interactions.
  • the antibody or fragment thereof comprises a set of six CDR sequences of an antibody selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19.
  • the antibody is selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19. Each possibility represents a separate embodiment of the invention.
  • the antibody or antibody fragment comprises three CDRs of a heavy-chain (HC) variable region comprising SEQ ID NO: 1 and three CDRs of a light-chain (LC) variable region comprising SEQ ID NO: 3.
  • HC heavy-chain
  • LC light-chain
  • CDR sequences of a given antibody molecule There are several methods known in the art for determining the CDR sequences of a given antibody molecule, but there is no standard unequivocal method. Determination of CDR sequences from antibody heavy and light chain variable regions can be made according to any method known in the art, including but not limited to the methods known as KAB AT, Chothia and IMGT.
  • a selected set of CDRs may include sequences identified by more than one method, namely, some CDR sequences may be determined using KABAT and some using IMGT, for example.
  • the CDR sequences of the mAb variable regions are determined using the IMGT method.
  • the antibody or fragment comprises the CDR sequences of a monoclonal antibody denoted CCM5.01, namely, the three CDR sequences contained in heavy chain variable region set forth in SEQ ID NO: 1 and the three CDR sequences contained in light chain variable region set forth in SEQ ID NO: 3.
  • the antibody or the antibody fragment comprises heavy-chain CDR1 comprising the sequence SDYAWN (SEQ ID NO: 5). According to some embodiments, the antibody or the antibody fragment comprises heavy-chain CDR2 comprising the sequence YITYSGSTSYNPSLKS (SEQ ID NO: 6). According to some embodiments, the antibody or the antibody fragment comprises heavy-chain CDR3 comprising the sequence ENRYDGEMFFDV (SEQ ID NO: 7).
  • the antibody or the antibody fragment comprises: (i) HC CDR1 comprising the sequence SDYAWN (SEQ ID NO: 5); (ii) HC CDR2 comprising the sequence YITYSGSTSYNPSLKS (SEQ ID NO: 6); and (iii) HC CDR3 comprising the sequence ENRYDGEMFFDV (SEQ ID NO: 7).
  • the antibody or the antibody fragment comprises lightchain CDR1 comprising the sequence RASQSISNDLH (SEQ ID NO: 8). According to some embodiments, the antibody or the antibody fragment comprises light-chain CDR2 comprising the sequence YAYQSIS (SEQ ID NO: 9). According to some embodiments, the antibody or the antibody fragment comprises light-chain CDR3 comprising the sequence QQSNSWPHT (SEQ ID NO: 10).
  • the antibody or the antibody fragment comprises: (i) LC CDR1 comprising the sequence RASQSISNDLH (SEQ ID NO: 8); (ii) LC CDR2 comprising the sequence YAYQSIS (SEQ ID NO: 9); and (iii) LC CDR3 comprising the sequence QQSNSWPHT (SEQ ID NO: 10).
  • the antibody or fragment comprises heavy chain CDR1 sequence comprising the sequence SDYAWN (SEQ ID NO: 5), heavy chain CDR2 comprising the sequence YITYSGSTSYNPSLKS (SEQ ID NO: 6), heavy chain CDR3 comprising the sequence ENRYDGEMFFDV (SEQ ID NO: 7), light chain CDR1 comprising the sequence RASQSISNDEH (SEQ ID NO: 8), light chain CDR2 comprising the sequence YAYQSIS (SEQ ID NO: 9), and light chain CDR3 comprising the sequence QQSNSWPHT (SEQ ID NO: 10), or analogs thereof comprising no more than 5% amino acid substitution, deletion and/or insertion in the hypervariable region (HVR) sequence.
  • HVR hypervariable region
  • the antibody or fragment comprises a set of six CDR sequences consisting of: i. heavy chain CDR1 having a sequence set forth in SEQ ID NO: 5; ii. heavy chain CDR2 having a sequence set forth in SEQ ID NO: 6; iii. heavy chain CDR3 having a sequence set forth in SEQ ID NO: 7; iv. light chain CDR1 having a sequence set forth in SEQ ID NO: 8; v. light chain CDR2 having a sequence set forth in SEQ ID NO: 9; and vi. light chain CDR3 having a sequence set forth in SEQ ID NO: 10
  • the antibody or fragment thereof comprises heavy chain variable region set forth in SEQ ID NO: 1, or an analog or derivative thereof having at least 90% sequence identity with the heavy chain variable region sequence.
  • the antibody or fragment thereof comprises light chain variable region set forth in SEQ ID NO: 3, or an analog thereof having at least 90% sequence identity with the light chain variable region sequence.
  • the antibody or fragment thereof comprises a heavy chain variable region having a sequence set forth in SEQ ID NO: 1, and a light chain variable region having a sequence set forth in SEQ ID NO: 3, or an analog thereof having at least 90% sequence identity with the light and/or heavy chain sequence.
  • the antibody is an isolated monoclonal antibody.
  • the antibody or fragment thereof recognizes human CEACAM1 with an affinity of at least 5xl0' 8 M. According to other embodiments, the antibody or antibody fragment binds with an affinity of 5xl0' 9 M, 10' 9 M, 5xl0' 10 M, 10' 10 M, or even higher to CEACAM1. According to some embodiments, the antibody or antibody fragment binds to human CEACAM1 with affinity at the range of 10' 9 M to 10' 10 M. Each possibility represents a separate embodiment of the invention.
  • antibodies of the present invention do not bind the N- domain of CEACAM1.
  • antibodies of the present invention bind CEACAM1, and cross-react with CEACAM5 and CEACAM8. According to other embodiments, antibodies of the present invention do not bind CEACAM3, CEACAM6 and CEACAM7.
  • the antibody or antibody fragment analog have at least 95% sequence identity with the hypervariable region of the reference antibody sequence.
  • the analog or derivative of the isolated antibody or fragment thereof has at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity with a variable region of the reference antibody sequence.
  • Each possibility represents a separate embodiment of the invention.
  • the antibody or antibody fragment according to the invention comprises a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 3, or an analog having at least 95% sequence similarity with said sequence.
  • the analog has at least 96, 97, 98 or 99% sequence identity with an antibody light or heavy chain variable regions described above.
  • the analog comprises no more than one amino acid substitution, deletion or addition to one or more CDR sequences of the hypervariable region, namely, any one of the CDR sequences set forth in SEQ ID NOs: 5, 6, 7, 8, 9, and 10. Each possibility represents a separate embodiment of the present invention.
  • the amino acid substitution is a conservative substitution.
  • the antibody or antibody fragment comprises a hypervariable region (HVR) having light and heavy chain regions defined above, in which 1, 2, 3, 4, or 5 amino acids were substituted, deleted and/or added.
  • HVR hypervariable region
  • the antibody or antibody fragment comprises a HVR having light and heavy chain regions defined above, in which one amino acid was substituted.
  • the antibody or antibody fragment comprises a CDR as defined above, in which one amino acid was substituted.
  • the present invention also provides antibodies and binding fragments thereof, comprising a heavy chain and a light chain, wherein said chains comprises heavy chain variable region sequence set forth in SEQ ID NO: 1 and light chain variable region sequence set forth in SEQ ID NO: 3.
  • the antibody or antibody fragment is capable of killing cancer cells.
  • the antibody is selected from the group consisting of a chimeric antibody and an antibody fragment comprising at least the antigen-binding portion of an antibody.
  • the antibody is a chimeric antibody.
  • the chimeric antibody comprises a human constant region.
  • the antibody fragment is selected from the group consisting of: Fab, Fab', F(ab')2, Fd, Fd', Fv, dAb, isolated CDR region, single chain variable region (scFV), single chain antibody (scab), "diabodies", and "linear antibodies".
  • Fab fragment of: Fab, Fab', F(ab')2, Fd, Fd', Fv, dAb, isolated CDR region, single chain variable region (scFV), single chain antibody (scab), "diabodies", and "linear antibodies”.
  • the antibody or antibody fragment comprises a heavy chain constant region selected from the group consisting of: mouse IgGl, mouse IgG2a, mouse IgG2b, mouse IgG3, human IgGl, human IgG2, human IgG3 and human IgG4.
  • a heavy chain constant region selected from the group consisting of: mouse IgGl, mouse IgG2a, mouse IgG2b, mouse IgG3, human IgGl, human IgG2, human IgG3 and human IgG4.
  • the antibody or antibody fragment comprises a mouse IgGl heavy chain constant region.
  • the monoclonal antibody is a chimeric monoclonal antibody.
  • the human constant regions of the chimeric antibody are selected from the group consisting of: human IgGl, human IgG2, human IgG3, and human IgG4.
  • a conjugate comprising the antibody or fragment thereof as described above is provided.
  • Antibodies or fragments thereof according to the present invention may be attached to a cytotoxic moiety, a radioactive moiety, or an identifiable moiety.
  • Polynucleotide sequences encoding antibodies, having specificity for CEACAM1 protein, as well as vectors and host cells carrying these polynucleotide sequences, are provided according to another aspect of the present invention.
  • polynucleotide sequences encoding the amino acid sequences of the heavy chain variable region and light chain variable region described above are provided.
  • the polynucleotide sequence encodes to the amino acid sequences of heavy chain variable region and light chain variable region of an antibody selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19.
  • the polynucleotide sequence encodes an antibody or antibody fragment or chain comprising at least one sequence set forth in SEQ ID NO: 1, and SEQ ID NO: 3.
  • the polynucleotide sequence according to the invention encodes an antibody or antibody fragment or chain comprising: a set of six CDRs wherein: heavy chain CDR1 sequence comprising the sequence SDYAWN (SEQ ID NO: 5), heavy chain CDR2 comprising the sequence YITYSGSTSYNPSLKS (SEQ ID NO: 6), heavy chain CDR3 comprising the sequence ENRYDGEMFFDV (SEQ ID NO: 7), light chain CDR1 comprising the sequence RASQSISNDLH (SEQ ID NO: 8), light chain CDR2 comprising the sequence YAYQSIS (SEQ ID NO: 9), and light chain CDR3 comprising the sequence QQSNSWPHT (SEQ ID NO: 10).
  • the polynucleotide sequences defined above encode a molecule selected from the group consisting of: an antibody, an antibody fragment comprising at least an antigen-binding portion, and an antibody conjugate comprising said antibody or antibody fragment.
  • a molecule selected from the group consisting of: an antibody, an antibody fragment comprising at least an antigen-binding portion, and an antibody conjugate comprising said antibody or antibody fragment.
  • the polynucleotide sequence encodes a monoclonal antibody heavy chain variable region comprising a sequence set forth in SEQ ID NO: 1 or a variant thereof having at least 90% sequence identity.
  • the polynucleotide sequence encodes a monoclonal antibody light chain variable region, comprising a sequence set forth in SEQ ID NO: 3, or a variant thereof having at least 90% sequence identity.
  • the polynucleotide encoding for the heavy chain comprises a sequence set forth in SEQ ID NO: 2 or a variant thereof having at least 90% sequence identity.
  • the polynucleotide encoding for the light chain comprises a sequence set forth in SEQ ID NO: 4 or a variant thereof having at least 90% sequence identity.
  • the polynucleotide encoding for the heavy chain comprises a sequence set forth in SEQ ID NO: 2 or a variant thereof having at least 95% sequence identity.
  • the polynucleotide encoding for the light chain comprises a sequence set forth in SEQ ID NO: 4 or a variant thereof having at least 95% sequence identity.
  • the polynucleotide encoding for the heavy chain comprises a sequence set forth in SEQ ID NO: 2.
  • the polynucleotide encoding for the light chain comprises a sequence set forth in SEQ ID NO: 4.
  • the present invention provides, according to some embodiments, a polypeptide comprising at least one sequence encoded by at least one polynucleotide sequence disclosed above.
  • the present invention provides a nucleic acid construct comprising a nucleic acid molecule encoding at least one antibody chain or fragment thereof according to the present invention.
  • the nucleic acid construct is a plasmid.
  • the plasmid comprises at least one polynucleotide sequence set forth in a sequence selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 4. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a cell capable of producing an antibody or an antibody fragment comprising the specific CDR sequences and/or specific heavy and light chain variable regions defined above.
  • a cell comprising at least one polynucleotide sequence disclosed above.
  • the cell producing the monoclonal antibody in a hybridoma cell.
  • the present invention provides, according to another aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising as an active ingredient, at least one antibody, antibody fragment or conjugates thereof, that recognizes CEACAM1, and optionally at least one pharmaceutical acceptable excipient, diluent, salt or carrier, wherein said at least one antibody or antibody fragment does not block the homophilic interactions of CEACAM1.
  • the pharmaceutical composition comprises a monoclonal antibody or a fragment thereof which is capable of binding to an epitope within the CEACAM1 protein to which binds a monoclonal antibody selected from the group consisting of: CCM5.01, CCM5.18, and CCM5.19.
  • the pharmaceutical composition comprises at least one monoclonal antibody comprising a set of six CDRs wherein: HC CDR1 is SEQ ID NO: 5; HC CDR2 is SEQ ID NO: 6; HC CDR3 is SEQ ID NO: 7; LC CDR1 is SEQ ID NO: 8; LC CDR2 is SEQ ID NO: 9; and LC CDR3 is SEQ ID NO: 10.
  • the pharmaceutical composition comprises an antibody or fragment thereof comprising a heavy chain variable region having a sequence set forth in SEQ ID NO: 1.
  • the pharmaceutical composition comprises an antibody or fragment thereof comprising a light chain variable region having a sequence set forth in SEQ ID NO: 3.
  • the pharmaceutical composition comprises an antibody or fragment thereof comprising a heavy chain variable region having the sequence set forth in SEQ ID NO: 1 and a light chain variable region having the sequence set forth in SEQ ID NO: 3.
  • the antibody, antibody fragment or antibody conjugate is capable of directly killing tumor cells independent of immune cells. According to certain embodiments, the antibody, antibody fragment or antibody conjugate does not interfere with the homophilic interactions of CEACAM1.
  • the pharmaceutical composition according to the present invention is for use in cancer immunotherapy. According to some embodiments, the pharmaceutical composition according to the present invention is for use in treating cancer.
  • the pharmaceutical composition further comprises an additional anti-cancer agent.
  • the cancer treatable with a composition according to the present invention may be any cancer that expresses CEACAM1. According to some embodiments, the cancer overexpresses CEACAM1.
  • the cancer is selected from the group consisting of a melanoma, a bladder cancer, a breast cancer, a prostate cancer, a gastric cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, a colon cancer, a cervical cancer, a kidney cancer, a lung cancer, a thyroid cancer, a brain cancer, a renal cancer, a throat cancer, a laryngeal carcinoma, a hepatic cancer, a fibrosarcoma, an endometrial cells cancer, a glioblastoma, sarcoma, a myeloid, a leukemia and a lymphoma.
  • a melanoma a bladder cancer, a breast cancer, a prostate cancer, a gastric cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, a colon cancer, a cervical cancer, a kidney cancer, a lung cancer, a thyroid cancer, a brain cancer, a renal cancer
  • the cancer is selected from the group consisting of a melanoma, a bladder cancer, a breast cancer, a prostate cancer, a non-small cell lung carcinoma (NSCLC), and a gastric cancer.
  • the cancer is melanoma.
  • the cancer is a solid cancer.
  • the solid cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, bladder cancer, pancreatic cancer, ovarian cancer, and colon cancer.
  • the pharmaceutical composition according to the present invention is for use in preventing or treating viral infection.
  • the viral infection is caused by a virus selected from the group consisting of viruses of the corona family and in particular SARS-CoV-2, influenza of any type (including but not limited to human, avian and swine strains), cytomegalovirus (CMV), Human immune deficiency virus (HIV), herpes virus and hepatitis virus.
  • viruses of the corona family and in particular SARS-CoV-2 influenza of any type (including but not limited to human, avian and swine strains), cytomegalovirus (CMV), Human immune deficiency virus (HIV), herpes virus and hepatitis virus.
  • the antibodies of the present invention may be used alone or in combination with at least one additional agent.
  • the additional agent is an anti-viral agent.
  • the additional agent is an anti-inflammatory agent.
  • the additional agent is an antibody activating inhibitory receptor on immune cells, including but not limited to anti-CD300a, anti-Siglec, anti-CD48 antibody and CD48Fc.
  • the anti CEACAM1 antibody is selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19.
  • the anti CEACAM1 antibody or antibody fragment comprises a set of six CDRs wherein: HC CDR1 is SEQ ID NO: 5; HC CDR2 is SEQ ID NO: 6; HC CDR3 is SEQ ID NO: 7; LC CDR1 is SEQ ID NO: 8; LC CDR2 is SEQ ID NO: 9; and LC CDR3 is SEQ ID NO: 10.
  • the present invention provides a method of treating cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one antibody, antibody fragment or conjugate thereof, that recognizes CEACAM1, the antibody, antibody fragment or conjugate thereof does not interfere with homophilic interactions of CEACAM1.
  • the therapeutically effective amount results in a decrease in tumor size or in the number of metastases in the subject.
  • the method of treating cancer comprises administering or performing at least one additional anti-cancer therapy.
  • the additional anticancer therapy is surgery, chemotherapy, radiotherapy, or immunotherapy.
  • the method of treating cancer comprises administration of the antibody that recognizes CEACAM1 protein as described herein, and an additional anticancer agent.
  • the additional anti-cancer agent is selected from the group consisting of: immune-modulator, activated lymphocyte cell, kinase inhibitor and chemotherapeutic agent.
  • the additional immune-modulator is an antibody, antibody fragment or antibody conjugate that binds to an antigen other than CEACAM1.
  • the subject is a human subject.
  • the present invention provides a method of diagnosing or prognosing cancer in a subject, the method comprises determining the expression level of CEACAM1 in a biological sample of said subject using at least one antibody as described herein.
  • the present invention provides a method of preventing or treating viral infection comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one antibody, antibody fragment or conjugate thereof, that recognizes CEACAM1, the antibody, antibody fragment or conjugate thereof does not interfere with homophilic interactions of CEACAM1.
  • the viral infection is caused by a virus selected from the group consisting of viruses of the corona family and in particular SARS-CoV-2, influenza of any type (including but not limited to human, avian and swine strains), cytomegalovirus (CMV), Human immune deficiency virus (HIV), herpes virus and hepatitis virus.
  • the method of preventing (after exposure for example), or treating viral infection comprises administering of the antibodies of the present invention alone or in combination with at least one additional agent.
  • the additional agent is an anti-viral agent.
  • the method comprises administering of an anti CEACAM1 antibody selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19.
  • the method comprises administration of an antibody or antibody fragment comprises a set of six CDRs wherein: HC CDR1 is SEQ ID NO: 5; HC CDR2 is SEQ ID NO: 6; HC CDR3 is SEQ ID NO: 7; LC CDR1 is SEQ ID NO: 8; LC CDR2 is SEQ ID NO: 9; and LC CDR3 is SEQ ID NO: 10.
  • the present invention further comprises, according to another aspect, a method of determining or quantifying CEACAM1 in a sample, the method comprising contacting a biological sample with an antibody or antibody fragment as described herein, and measuring the level of complex formation.
  • the antibody is selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19.
  • the antibody or antibody fragment comprises a set of six CDRs wherein: HC CDR1 is SEQ ID NO: 5; HC CDR2 is SEQ ID NO: 6; HC CDR3 is SEQ ID NO: 7; LC CDR1 is SEQ ID NO: 8; LC CDR2 is SEQ ID NO: 9; and LC CDR3 is SEQ ID NO: 10.
  • Determining and quantifying methods may be performed in-vitro or ex-vivo according to some embodiments or may be used in diagnosing conditions associated with expression of CEACAM1.
  • the antibodies according to the present invention may be also used to configure screening methods.
  • an enzyme-linked immunosorbent assay (ELISA), or a radioimmunoassay (RIA), as well as method such as IHC or FACS can be constructed for measuring levels of polypeptides using the antibodies and methods known in the art.
  • the method for detecting or quantifying the presence of CEACAM1 expressed on cells or secreted to a biological medium comprises the steps of: i. incubating a sample with an antibody specific to CEACAM1 or an antibody fragment thereof as described herein; and ii. detecting the bound CEACAM1 using a detectable probe.
  • the method further comprises the steps of: iii. comparing the amount of (ii) to a standard curve obtained from a reference sample containing a known amount of CEACAM1; and iv. calculating the amount of the CEACAM1 in the sample from the standard curve.
  • the sample is body fluid.
  • the method is performed in-vitro or ex-vivo.
  • a kit for measuring the expression or presence of CEACAM1 in biological sample comprising at least one antibody or antibody fragment according to the present invention.
  • the kit comprises an antibody selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19.
  • the kit comprises an antibody or antibody fragment comprising a set of six CDRs wherein: HC CDR1 is SEQ ID NO: 5; HC CDR2 is SEQ ID NO: 6; HC CDR3 is SEQ ID NO: 7; LC CDR1 is SEQ ID NO: 8; LC CDR2 is SEQ ID NO: 9; and LC CDR3 is SEQ ID NO: 10.
  • the present invention provides a kit for detecting cancer, the diagnostic kit comprises an antibody or antibody fragment thereof as described herein.
  • Figure 1 shows staining of parental 721.221 cells (left column) with the 3 anti- CEACAM1 mAbs: CCM5-1 (CCM5.01), CCM5-18 (CCM5.18) and CCM5-19 (CCM5.19).
  • the staining of the CEACAM1 transfected 721.221 cells is shown in the right column. The staining was performed using various quantities (2pl, 5pl, lOpl, 20pl, empty histograms) of hybridomas supernatants.
  • Figure 2 shows staining of 721.221 cells expressing CEACAM1 with CEACAM1 -Ig incubated with the various anti- CEACAM1 mAbs: CCM5-1, CCM5-18 and CCM5-19 at various amounts as indicated (2pl, 5pl, lOpl, 20pl, empty histograms).
  • Figure 3 shows the binding of the mAbs to CEACAMl-IgG fusion protein.
  • Microscale thermophoresis (MST) binding measurements of anti-CEACAMl mAbs to CEACAM1 is shown.
  • the CEACAM1 fusion protein concentration was kept constant (7.5 nM), and the concentration of the mAbs varied from 30 mM to 0.1 nM.
  • the binding Kd was obtained using the Hill method using the NanoTemper analysis software. Error bars represent standard error of 5 measurements.
  • Figure 4 shows staining of parental 1106mel cells with the 3 anti-CEACAMl mAbs: CCM5- 1, CCM5-18 and CCM5-19.
  • Figure 5 shows the effect of anti-CEACAMl mAbs on melanoma cell death. Death was determined using PI staining.
  • Figures 6A-6B show the combined effect of anti-CEACAMl and Cisplatin on Mel-14 cell viability.
  • Figures 7A-7B show tumor growth and weight progression of human melanoma cell line (Mel- 14) transplanted as a xenograft in SCID/beige mice.
  • Figure 7A Tumor growth was measured using a caliper every other day until the first mice had a tumor of -15 mm 3 . Tumor size was calculated by the formula: width 2 x length/2.
  • Figure 7B Tumor weight after transplanting different amounts of cells. Each point indicates tumor characteristics of a single mouse.
  • Figures 8A-8C show the effect of anti- CEACAM1 on tumor growth of Mel-14 cell xenograft in SCID/Beige mice.
  • Figure 8A A schematic representation of the treatment schedule.
  • Mel- 14 cells (5xl0 6 / 200 pl) were injected subcutaneously (sc) into SCID/beige mice at day 0.
  • Intraperitoneal injections (ip) of anti-CEACAMl or IgGl (as negative control) were performed 30 min later and then every other day until tumors reached 15 mm 3 . At this time, mice were euthanized, tumor excised and weighted.
  • Figures 8B-8C Tumor weight (mg) of anti-CEACAMl or IgGl treated mice with dose of 50 pg/kg (B) and 500 pg/kg (C).
  • Figure 9 shows flow cytometry staining of A549 human lung carcinoma cells using anti- CEACAMl (empty histogram) or the negative isotype control IgGl (filled histogram).
  • One representative experiment of at least 3 is presented.
  • FIGS 10A-10D show the effect of anti-CEACAMl mAb on immune cells of transgenic mice expressing CEACAM1 following injection of B16-F10 melanoma cells.
  • Figure 10A Schematic representation of the treatment schedule of B16-F10 cells grafted mice. B16-F10 cells (5X10 5 /100 pl) were injected subcutaneously (sc) into hCeacaml +l+ x in.sCeacam I '' mice at day 0.
  • Intraperitoneal injections ip
  • ip Intraperitoneal injections (ip) of anti-hCeacaml, anti-mCeacaml or mlgGl (lOOpg/mice) were performed after day 8 (palpable tumor) and then every other day until tumors reached 15mm 3 and mice were euthanized.
  • Figures 10B and 10C Tumor size (mm 3 , B) and weight of treated mice (C).
  • Figure 10D - number of CD3 T cells in spleen of euthanized mice (3 mice/group).
  • Figure 11 shows the binding of anti-CEACAMl mAbs (EC-Sab3, B3-17, and CCM5.01) to CEACAM1 molecule that includes (CCl-Fc) or lacks (CCldN-Fc) the N-terminal domain. Binding was assessed by absorbance using spectrophotometer at 450nm.
  • Figures 12A and 12B show CEACAM1 expression of eosinophils from healthy donor and 4 Covid-19 patients, as detected by anti hCEACAMl mAb CCM5.01.
  • Figure 12A Representative histogram of CEACAM1 expression.
  • Figure 12B CEACAM1 expression as staining index.
  • Figure 13 depicts the binding of mAbs CCM5.01, CCM5.19, and F1-C5 to CEACAMl-Fc:
  • CEACAM1 fusion protein and CEACAMl-dN-Fc CEACAM1 fusion protein that does not contain the N-terminal domain, compared to CCl/3/5-Sab positive control and isotype matched negative control mAh. Data are representative of three independent experiments.
  • Figure 14 demonstrates the binding of mAbs CCM5.01 and CCM5.19 and respective positive control antibodies, to CHO, CHO-mouse CEACAM1, CHO-human CEACAM1, CHO-human CEACAM3, CHO-human CEACAM5, CHO-human CEACAM6, CHO-human CEACAM7, and CHO-human CEACAM8 transfectants. Data shown represent the median values of one out of three different, representative experiments.
  • Figures 15A-15B show the effect of CCM5.01 mAb on colon cells death.
  • Colon cancer cell lines HT-29 ( Figure 15b) and LoVo cells ( Figure 15A) transfected with long (L) or short (S) CEACAM1 isoforms were incubated with CCM5.01 for 72hr. Cell death was then determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium reduction (MTT) assay.
  • MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium reduction
  • the present invention provides antibodies specific to the human protein CEACAM1 that are effective in inhibition of tumor growth.
  • the invention also provides production and use of the antibodies as therapeutic agents.
  • the mAbs of the present invention may be used for augmenting anti-tumor killing activity, and as diagnostic reagents.
  • the invention provides antibodies specific to CEACAM1 for efficient induction of apoptosis of cancer cells.
  • the antibodies of the invention induce an inhibitory effect directly on the tumor cells, without dependency on immune components.
  • the inhibitory signal induced by the antibodies is mediated by the phosphorylation of the SH2 domain-containing protein tyrosine phosphatase- SHP1, inducing apoptosis of the tumor cells by increase and activation of the tumor suppressor protein p53 (Zaffran et al., Cancer Gene Therapy, 29; 1676-1685 (2022)). This is in contrast to other known anti-CEACAMl antibodies that inhibit the inhibitory signal induced by the tumor cells on immune cells.
  • Viruses are evidently associated with respiratory infections ranging in severity from the common cold to pneumonia and death. More than 200 viral types have been associated with the common cold, of which 50% of infections are rhinovirus, but also respiratory syncitial virus, influenza - and coronaviruses, particularly human coronavirus- 229E (HCoV-229E), which is ‘relatively benign’. Although monocytes are much more resistant to HCoV-229E, dendritic cells are rapidly killed by the virus.
  • Dendritic cells are the sentinel cells in the respiratory tract, and plasmacytoid dendritic cells are a crucial antiviral defense via interferon production. Thus, these viruses can impair control of viral dissemination and the formation of long-lasting immune memory.
  • the cellular receptor for HcoV-229E is CD- 13 (aminopeptidase-N).
  • the cellular receptors for coronaviruses are critical for cell entry.
  • Severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and HCoV-NL63 bind to angiotensin converting enzyme 2 (ACE2) on ciliated cells in the respiratory tract, the crystal structure is known (Song et al., 2018).
  • SARS-CoV spike (S) glycoprotein (with S 1 and S2 sub-units) on the outer envelope binds to ACE2, fusing viral and cellular membranes, triggering conformational transformations. Cleavage of the S1/S2 subunits by proteases is critical.
  • SARS-CoV infection involved receptor binding, conformational changes receptor binding and subsequent cathepsin L (and type II transmembrane serine proteases) proteolysis within endosomes - with inhibitors of cathepsin L preventing viral entry.
  • SARS- CoV may lead to markedly elevated cytokine levels, leading to tissue damage, pneumonitis, and acute respiratory distress syndrome (ARDS).
  • ARDS acute respiratory distress syndrome
  • the spike proteins in SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) are crucial for host specificity and jumping between species, e.g.
  • ACE2 has been identified as a receptor for the novel coronavirus that was identified as the cause of the respiratory disease outbreak in Wuhan in late 2019 (referred to as 2019 - nCoV by the WHO, or Wuhan coronavirus).
  • 2019-nCoV is a beta coronavirus, and, in common with the SARS-C0V8, the viral spike protein engages ACE2 for viral entry.
  • the data presented by Letko and Munzter (BiorXiv7) is preliminary and has not been peer-reviewed, but a rapid pace of research is needed in the present circumstances.
  • ACE2 receptor expression is highly expressed in type II alveolar cells (AT2) with much individual variation and the authors reported that the cells also expressed many genes involved in viral reproduction and transmission. While these findings are preliminary, the rapid publications in bioRxiv and similar archives are crucial in what is now officially a global health emergency.
  • viruses including influenza virus, human cytomegalovirus and murine corona virus induce CEACAM1 expression on epithelia and endothelial cells and on cells of the immune system.
  • Viruses use CEACAM1 to enter and infect these cells.
  • CEACAM1 suppresses the viruses in an SHP2-dependent process and achieves this also by suppressing mTOR-mediated protein biosynthesis.
  • the antibodies of the present invention activate CEACAM1 receptor ITIMs to dephosphorylate various signal transduction proteins via SHP-1 and SHP-2 phosphatases and therefore have an anti-viral activity and protect the cells from killing by viral infection.
  • the anti-CEACAMl activating antibodies of the present invention are effectors in a broad antiviral activity by at least one of the following mechanisms: i. binding to cell associated membrane CEACAM1, expressed for example on lung epithelial cells, lung dendritic cells and other immune cells, and therefore stimulating anti-viral activity. ii. competing with virus CEACAM-1 binding to the cell surface CEACAM1. iii. binding to virus CEACAM-1 and therefore antagonize its binding to the cell surface CEACAM1.
  • the antibodies described herein are according to some embodiments for use in treating viral infection.
  • the viral infection is caused by a virus selected from the group consisting of viruses of the corona family and in particular SARS-CoV-2, influenza of any type (including but not limited to human, avian and swine strains), cytomegalovirus (CMV), Human immune deficiency virus (HIV), herpes virus and hepatitis virus.
  • viruses of the corona family and in particular SARS-CoV-2 influenza of any type (including but not limited to human, avian and swine strains), cytomegalovirus (CMV), Human immune deficiency virus (HIV), herpes virus and hepatitis virus.
  • the antibodies of the present invention may be used alone or in combination with at least one additional agent.
  • the additional agent is an anti-viral agent. According to other embodiments, the additional agent is an anti-inflammatory agent.
  • antigen refers to a molecule or a portion of a molecule capable of eliciting antibody formation and being specifically bound by an antibody.
  • An antigen may have one or more than one epitope. The specific binding referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.
  • An antigen according to some embodiments of the present invention is a CEACAM protein. According to specific embodiments, the antigen is CEACAM 1.
  • CEACAM1 is used to refer to the protein product of the CEACAM1 gene e.g., NP_001020083.1, NP_001703.2. In humans, 11 different CEACAM 1 splice variants have been detected so far. Individual CEACAM 1 isoforms differ with respect to the number of extracellular immunoglobulin-like domains (for example, CEACAM 1 with four extracellular immunoglobulin-like domains is known as CEACAM 1-4), membrane anchorage and/or the length of their cytoplasmic tail (for example, CEACAM 1-4 with a long cytoplasmic tail is known as CEACAM 1-4L and CEACAM 1-4 with a short cytoplasmic tail is known as CEACAM 1-4S).
  • the N-terminal domain of CEACAM 1 starts immediately after the signal peptide and its structure is regarded as IgV-type.
  • the N-terminal IgV-type domain is comprised of 108 amino acids, from amino acid 35 to 142. This domain was identified as responsible for the homophilic binding activity (Watt et al., 2001, Blood. 98, 1469-79). All variants, including these splice variants are included within the term “CEACAM 1”.
  • the antibodies or a fragment thereof according to the invention bind to an epitope in CEACAM 1. Specifically, the antibodies bind to an epitope within the ectodomain (extracellular part) of the CEACAM 1 protein. According to some embodiments, antibodies of the present invention do not bind the N-domain of CEACAM 1.
  • antibodies of the present invention bind CEACAM 1, and cross-react with CEACAM5 and CEACAM8. According to other embodiments, antibodies of the present invention do not bind CEACAM3, CEACAM6 and CEACAM7.
  • antigenic determinant or “epitope” as used herein refers to the region of an antigen molecule that specifically reacts with a particular antibody.
  • Peptide sequences derived from an epitope can be used, alone or in conjunction with a carrier moiety, applying methods known in the art, to immunize animals and to produce additional polyclonal or monoclonal antibodies. Isolated peptides derived from an epitope may be used in diagnostic methods to detect antibodies.
  • the affinity can be quantified using known methods such as, Surface Plasmon Resonance (SPR), and can be calculated using, e.g., a dissociation constant, Kd, such that a lower Kd reflects higher affinity.
  • SPR Surface Plasmon Resonance
  • Antibodies, or immunoglobulins comprise two heavy chains linked together by disulfide bonds and two light chains, each light chain being linked to a respective heavy chain by disulfide bonds in a "Y" shaped configuration. Proteolytic digestion of an antibody yields Fv (Fragment variable) and Fc (Fragment crystallizable) domains.
  • the antigen binding domains, Fab include regions where the polypeptide sequence varies.
  • the term F(ab')2 represents two Fab' arms linked together by disulfide bonds.
  • Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains (CH).
  • Each light chain has a variable domain (VL) at one end and a constant domain (CL) at its other end, the light chain variable domain being aligned with the variable domain of the heavy chain and the light chain constant domain being aligned with the first constant domain of the heavy chain (CHI).
  • VL variable domain
  • CL constant domain
  • CHI first constant domain of the heavy chain
  • the variable domains of each pair of light and heavy chains form the antigen-binding site.
  • the domains on the light and heavy chains have the same general structure and each domain comprises four framework regions, whose sequences are relatively conserved, joined by three hyper-variable domains known as complementarity determining regions (CDRs 1-3). These domains contribute specificity and affinity of the antigen-binding site.
  • CDR identification or determination from a given heavy or light chain variable sequence is typically made using one of few methods known in the art. For example, such determination is made according to the Kabat (Wu T.T and Kabat E.A., J Exp Med, 1970; 132:211-50) and IMGT (Lefranc M-P, et al., Dev Comp Immunol, 2003, 27:55-77).
  • CDR having a sequence includes options wherein the CDR comprises the specified sequences and also options wherein the CDR consists of the specified sequence.
  • the antigen specificity of an antibody is based on the hyper variable region (HVR), namely the unique CDR sequences of both light and heavy chains that together form the antigen-binding domain (ABD).
  • HVR hyper variable region
  • the isotype of the heavy chain (gamma, alpha, delta, epsilon or mu) determines immunoglobulin class (IgG, IgA, IgD, IgE or IgM, respectively).
  • the light chain is either of two isotypes (kappa, K or lambda, ). Both isotopes are found in all antibody classes.
  • antibody is used in the broadest sense and includes monoclonal antibodies (including full length or intact monoclonal antibodies), polyclonal antibodies, multivalent antibodies, and antibody fragments long enough to exhibit the desired biological activity, namely binding to CEACAM1.
  • Antibody or antibodies according to the invention includes intact antibodies, such as polyclonal antibodies or monoclonal antibodies (mAbs), as well as proteolytic fragments thereof, such as the Fab or F(ab')2 fragments. Single chain antibodies also fall within the scope of the present invention.
  • Antibody fragments comprise only a portion of an intact antibody, generally including an antigen binding site of the intact antibody and thus retaining the ability to bind antigen.
  • Examples of antibody fragments encompassed by the present definition include: (i) the Fab fragment, having VE, CL, VH and CHI domains; (ii) the Fab' fragment, which is a Fab fragment having one or more cysteine residues at the C-terminus of the CHI domain; (iii) the Fd fragment having VH and CHI domains; (iv) the Fd' fragment having VH and CHI domains and one or more cysteine residues at the C-terminus of the CHI domain; (v) the Fv fragment having the VL and VH domains of a single arm of an antibody; (vi) the dAb fragment (Ward et al., Nature 1989, 341, 544-546) which consists of a VH domain; (vii) isolated CDR regions; (viii) F(ab')2 fragments, a
  • the antibody fragments can be isolated from antibody phage libraries.
  • Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (Carter et al., Bio/Technology 70:163- 167 (1992)).
  • F(ab')2 fragments can be isolated directly from recombinant host cell culture.
  • Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.
  • the antibody of choice is a single chain Fv fragment (scFv).
  • Single chain antibodies can be single chain composite polypeptides having antigen binding capabilities and comprising amino acid sequences homologous or analogous to the variable regions of an immunoglobulin light and heavy chain i.e. linked VH-VL or single chain Fv (scFv).
  • Techniques for the production of single-chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single-chain antibodies to CEACAM1.
  • mAb monoclonal antibody
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigen. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
  • the modifier "monoclonal” is not to be construed as requiring production of the antibody by any particular method. mAbs may be obtained by methods known to those skilled in the art.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature 1975, 256, 495-7, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
  • Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described, for example, in Clackson et al., Nature 1991, 352, 624-628 or Marks et al., J. Mol. Biol., 1991, 222:581-597.
  • VH variable heavy
  • VL variable light
  • the mAbs of the present invention may be of any immunoglobulin class including IgG, IgM, IgE, IgA, and IgD.
  • a hybridoma producing a mAb may be cultivated in-vitro or in-vivo. High titers of mAbs can be obtained by in-vivo production where cells from the individual hybridomas are injected intra-peritoneally into pristine-primed Balb/c mice to produce ascites fluid containing high concentrations of the desired mAbs.
  • mAbs may be purified from such ascites fluids, or from culture supernatants, using methods well known to those of skill in the art.
  • Anti-idiotype antibodies specifically immunoreactive with the hypervariable regions of an antibody of the invention are also comprehended.
  • the invention provides a monoclonal antibody or an antibody fragment comprising an antigen binding domain (ABD) which comprises three CDRs of a light chain and three CDRs of a heavy chain, wherein said ABD has at least 90% sequence identity or similarity with an ABD of a monoclonal mouse antibody selected from the group consisting of CCM5.01, CCM5.18, and CCM5.19.
  • ABD antigen binding domain
  • the ABD has at least 90% sequence identity or similarity with an ABD of a monoclonal mouse antibody comprising a heavy variable chain comprising the amino acid sequence SEQ ID NO: 1 and a light variable chain comprising the amino acid sequence SEQ ID NO: 3 (herein identified as CCM5.01).
  • Such antibody may have an ABD domain having at least 93%, at least 94%, at least 95%, at least 96, at least 97, at least 98, at least 99% sequence identity or similarity or 100% sequence identity with corresponding ABD of antibodies CCM5.01, CCM5.18, or CCM5.19.
  • Sequence identity is the amount of amino acids or nucleotides which match exactly between two different sequences. Sequence similarity permits conservative substitution of amino acids to be determined as identical amino acids.
  • the invention also provides conservative amino acid variants of the antibody molecules according to the invention. Variants according to the invention also may be made that conserve the overall molecular structure of the encoded proteins. Given the properties of the individual amino acids comprising the disclosed protein products, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, "conservative substitutions,” may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
  • antibody analog refers to an antibody derived from another antibody by one or more conservative amino acid substitutions.
  • antibody variant refers to any molecule comprising the antibody of the present invention.
  • fusion proteins in which the antibody or an antigen-binding-fragment thereof is linked to another chemical entity is considered an antibody variant.
  • Analogs and variants of the antibody sequences are also within the scope of the present application. These include, but are not limited to, conservative and non-conservative substitution, insertion and deletion of amino acids within the sequence. Such modification and the resultant antibody analog or variant are within the scope of the present invention as long as they confer, or even improve the binding of the antibody to the CEACAM1.
  • Conservative substitutions of amino acids as known to those skilled in the art are within the scope of the present invention.
  • Conservative amino acid substitutions include replacement of one amino acid with another having the same type of functional group or side chain, e.g., aliphatic, aromatic, positively charged, negatively charged. These substitutions may enhance oral bioavailability, penetration, and targeting to specific cell populations, immunogenicity, and the like.
  • One of skill will recognize that individual substitutions, deletions or additions to a peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.
  • Conservative substitution tables providing functionally similar amino acids are well known in the art. For example, according to one table known in the art, the following six groups each contain amino acids that are conservative substitutions for one another:
  • variant chain sequences are determined by sequencing methods using specific primers. Different sequencing methods employed on the same sequence may result in slightly different sequences due to technical issues and different primers, particularly in the sequence terminals.
  • molecule having the antigen-binding portion of an antibody and “antigen- binding-fragments” as used herein are intended to include not only intact immunoglobulin molecules of any isotype and generated by any animal cell line or microorganism, but also the antigen-binding reactive fraction thereof, including, but not limited to, the Fab fragment, the Fab' fragment, the F(ab')2 fragment, the variable portion of the heavy and/or light chains thereof, Fab mini-antibodies (see e.g., WO 93/15210, US patent application 08/256,790, WO 96/13583, US patent application 08/817,788, WO 96/37621, US patent application 08/999,554), and single-chain antibodies incorporating such reactive fraction, as well as any other type of molecule in which such antibody reactive fraction has been physically inserted.
  • Such molecules may be provided by any known technique, including, but not limited to, enzymatic cleavage, peptide synthesis or recombinant techniques.
  • the antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species, or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 57:6851- 6855 (1984)).
  • complementarity determining region (CDR) grafting may be performed to alter certain properties of the antibody molecule including affinity or specificity.
  • CDR complementarity determining region
  • Chimeric antibodies are molecules of which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Antibodies that have variable region framework residues substantially from human antibody (termed an acceptor antibody) and CDRs substantially from a mouse antibody (termed a donor antibody) are also referred to as humanized antibodies. Chimeric antibodies are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine mAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric mAbs are used. Chimeric antibodies and methods for their production are known in the art (for example PCT patent applications Nos.
  • the antibody is a monoclonal antibody.
  • the monoclonal antibody is a chimeric monoclonal antibody.
  • the chimeric antibody comprises human-derived constant regions.
  • the human constant regions of the chimeric antibody are selected from the group consisting of: human IgGl, human IgG2, human IgG3, and human IgG4.
  • a chimeric monoclonal antibody which recognizes CEACAM1 comprising a set of six CDRs wherein: HC CDR1 is (SEQ ID NO: 5); HC CDR2 is (SEQ ID NO: 6); HC CDR3 is (SEQ ID NO: 7); LC CDR1 is (SEQ ID NO: 8); LC CDR2 is (SEQ ID NO: 9); and LC CDR3 is (SEQ ID NO: 10).
  • the active agent is preferably utilized together with one or more pharmaceutically acceptable carrier(s) and optionally any other therapeutic ingredients.
  • the carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.
  • the active agent is provided in an amount effective to achieve the desired pharmacological effect, as described above, and in a quantity appropriate to achieve the desired exposure.
  • the antibodies and fragments and conjugates thereof of the present invention comprising the antigen binding portion of an antibody or comprising another polypeptide including a peptide-mimetic will be suspended in a sterile saline solution for therapeutic uses.
  • compositions may alternatively be formulated to control release of active ingredient (molecule comprising the antigen binding portion of an antibody) or to prolong its presence in a patient's system.
  • active ingredient molecule comprising the antigen binding portion of an antibody
  • suitable drug delivery systems include, e.g., implantable drug release systems, hydrogels, hydroxymethylcellulose, microcapsules, liposomes, microemulsions, microspheres, and the like.
  • Controlled release preparations can be prepared through the use of polymers to complex or adsorb the molecule according to the present invention.
  • biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid.
  • the rate of release of the molecule according to the present invention, i.e., of an antibody or antibody fragment, from such a matrix depends upon the molecular weight of the molecule, the amount of the molecule within the matrix,
  • composition of this invention may be administered by any suitable means, such as orally, topically, intranasally, subcutaneously, intramuscularly, intravenously, intra-arterially, intraarticulary, intralesionally, intratumorally or parenterally.
  • suitable means such as orally, topically, intranasally, subcutaneously, intramuscularly, intravenously, intra-arterially, intraarticulary, intralesionally, intratumorally or parenterally.
  • intravenous (i.v.) administration is used for delivering antibodies.
  • the therapeutically effective amount of the molecule according to the present invention will depend, inter alia upon the administration schedule, the unit dose of molecule administered, whether the molecule is administered in combination with other therapeutic agents, the immune status and health of the patient, the therapeutic activity of the molecule administered, its persistence in the blood circulation, and the judgment of the treating physician.
  • the term "therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal.
  • the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the disorder.
  • the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
  • efficacy in vivo can, for example, be measured by assessing the duration of survival, time to disease progression (TTP), the response rates (RR), duration of response, and/or quality of life.
  • the cancer amendable for treatment by the present invention includes, but is not limited to: melanoma, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer, lung cancer (including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung), cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulva cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma (including low grade/follicular non-Hodgkin
  • the cancer is selected from the group consisting of breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma, Kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, melanoma, ovarian cancer, mesothelioma, and multiple myeloma.
  • the cancerous conditions amendable for treatment of the invention include metastatic cancers.
  • the pharmaceutical composition according to the invention is for use in treating cancer characterized by overexpression of CEACAM1.
  • the molecules of the present invention as active ingredients are dissolved, dispersed or admixed in an excipient that is pharmaceutically acceptable and compatible with the active ingredient as is well known.
  • excipients are, for example, water, saline, phosphate buffered saline (PBS), dextrose, glycerol, ethanol, or the like and combinations thereof.
  • PBS phosphate buffered saline
  • dextrose glycerol
  • ethanol ethanol
  • suitable carriers are well known to those skilled in the art.
  • the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents.
  • the pharmaceutical composition according to the present invention may be administered together with an anti-neoplastic composition.
  • treatment refers to both therapeutic treatment and prophylactic or preventative measures.
  • cancer refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • examples of cancer include but are not limited to, melanoma, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include melanoma, lung, thyroid, breast, colon, prostate, hepatic, bladder, renal, gastric, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary, or endometrial cancer.
  • the method of treating cancer comprises administering the pharmaceutical composition as part of a treatment regimen comprising administration of at least one additional anti-cancer agent.
  • the anti-cancer agent is selected from the group consisting of an antimetabolite, a mitotic inhibitor, a taxane, a topoisomerase inhibitor, a topoisomerase II inhibitor, an asparaginase, an alkylating agent, an antitumor antibiotic, and combinations thereof.
  • an antimetabolite a mitotic inhibitor, a taxane, a topoisomerase inhibitor, a topoisomerase II inhibitor, an asparaginase, an alkylating agent, an antitumor antibiotic, and combinations thereof.
  • Monoclonal antibodies according to the present invention may be used as part of combined therapy with at least one anti-cancer agent.
  • the additional anti-cancer agent is an immuno-modulator, an activated lymphocyte cell, a kinase inhibitor or a chemotherapeutic agent.
  • the anti-cancer agent is an immuno-modulator, whether agonist or antagonist, such as antibody against an immune checkpoint molecule.
  • Immune checkpoint pathways consist of a range of co-stimulatory and inhibitory molecules which work in concert in order to maintain self-tolerance and protect tissues from damage by the immune system under physiological conditions. Tumors take advantage of certain checkpoint pathways in order to evade the immune system. Therefore, the inhibition of such pathways has emerged as a promising anti-cancer treatment strategy.
  • the additional anti-cancer agent is a chemotherapeutic agent.
  • the pharmaceutical composition according to the present invention is for use in treating cancer or for use in enhancing the immune response.
  • enhancing immune response refers to increasing the responsiveness of the immune system and inducing or prolonging its memory.
  • the pharmaceutical composition according to the present invention may be used to stimulate immune system upon vaccination.
  • the pharmaceutical composition can be used for improving vaccination.
  • the cancer is selected from lung, thyroid, breast, colon, melanoma, prostate, hepatic, bladder, renal, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary, and endometrial cells cancer.
  • lung thyroid, breast, colon, melanoma, prostate, hepatic, bladder, renal, cervical, pancreatic, leukemia, lymphoma, myeloid, ovarian, uterus, sarcoma, biliary, and endometrial cells cancer.
  • a pharmaceutical composition comprising at least one antibody or fragment thereof according to the present invention, and a pharmaceutical composition, comprising an additional immuno-modulator or a kinase inhibitor, are used in treatment of cancer by separate administration.
  • the present invention provides a method of treating cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a monoclonal antibody or antibody fragment according to the present invention.
  • the term “effective amount” as used herein refers to a sufficient amount of the monoclonal antibody or the antibody fragment that, when administered to a subject will have the intended therapeutic effect.
  • the effective amount required to achieve the therapeutic end result may depend on a number of factors including, for example, the specific type of the tumor and the severity of the patient's condition, and whether the combination is further coadministered with radiation.
  • the effective amount (dose) of the active agents, in the context of the present invention should be sufficient to affect a beneficial therapeutic response in the subject over time, including but not limited to inhibition of tumor growth, reduction in the rate of tumor growth, prevention of tumor and metastasis growth and enhanced survival.
  • administering or “administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art.
  • a compound or an agent can be administered enterally or parenterally.
  • Parenteral administration includes administration intravenously, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, intranasally, by inhalation, intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct).
  • a compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent.
  • Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
  • the administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug.
  • a physician who instructs a patient to self-administer a drug, or to have the drug administered by another and/or who provides a patient with a prescription for a drug is administering the drug to the patient.
  • Antibodies are generally administered in the range of about 0.1 to about 20 mg/kg of patient weight, commonly about 0.5 to about 10 mg/kg, and often about 1 to about 5 mg/kg. In this regard, it is preferred to use antibodies having a circulating half-life of at least 12 hours, preferably at least 4 days, more preferably up to 21 days. Chimeric antibodies are expected to have circulatory half-lives of up to 14-21 days. In some cases, it may be advantageous to administer a large loading dose followed by periodic (e.g., weekly) maintenance doses over the treatment period. Antibodies can also be delivered by slow-release delivery systems, pumps, and other known delivery systems for continuous infusion.
  • the present invention also provides a method of preventing or treating a viral infection comprising administering to a subject at least one antibody specific to CEACAM1 as described herein, or a fragment thereof comprising at least the antigen binding domain.
  • the present invention further discloses methods for diagnosing and prognosing cancer.
  • the present invention provides a diagnostic and/or prognostic method of cancer or infectious disease in a subject, the method comprises the step of determining the expression level of CEACAM1 in a biological sample of said subject using at least one antibody as described herein.
  • biological sample encompasses a variety of sample types obtained from an organism that may be used in a diagnostic or monitoring assay.
  • the term encompasses blood and other liquid samples of biological origin, solid tissue samples, such as a biopsy specimen, or tissue cultures or cells derived therefrom and the progeny thereof. Additionally, the term may encompass circulating tumor or other cells.
  • the term specifically encompasses a clinical sample, and further includes cells in cell culture, cell supernatants, cell lysates, serum, plasma, urine, amniotic fluid, biological fluids including aqueous humour and vitreous for eyes samples, and tissue samples.
  • the term also encompasses samples that have been manipulated in any way after procurement, such as treatment with reagents, solubilisation, or enrichment for certain components.
  • Determining the expression level of CEACAM1 can be performed by a labeled anti- CEACAM1 antibody as described herein. Determining the expression can be performed, for example, by ELISA or by flow cytometry.
  • the method of the invention can further comprise the step of comparing said level of expression to a control level.
  • HC4 hepatocellular carcinoma, LS174 colon cancer, PANC-1 pancreatic cancer, ES-2 ovarian cancer and LOVO colorectal adenocarcinoma cell lines (provided by Dr. Joseph Tam and Prof. Rachel Bar-Shavit, Hebrew University of Jerusalem and Hadassah Medical Center, Israel) were cultured in DMEM (Gibco-ThermoFisher) supplemented with 10% FBS (Sigma), L-glutamine (2 mM), penicillin (100 lU/ml) + streptomycin (100 pg/ml) (Biological Industries). All cell lines were periodically checked for the CEACAM1 membrane expression by flow cytometry (FC).
  • FC flow cytometry
  • melanoma The viability of melanoma (Mel) and LOVO cells was determined by MTT assay (Sigma, MO, USA).
  • Melanoma cells (5xl0 3 /100pl) were seeded in a flat bottom 96 well cell culture plate (Thermo Scientific Nunc, Qiryat Shemona, Israel) in their respective culture medium and incubated over night at 37°C in 5% CO 2 .
  • the medium was then replaced with fresh DMEM 10% FCS containing different concentrations (0.1, 1, 5, and lOpg/ml) of anti-CEACAMl mAbs (clones 01 & 19), or IgGl isotype control (Mouse IgGl K Isotype Control Purified, without azide, eBioscience, ThermoFisher).
  • Cell viability was determined after 72hr (a time point that was found to be the optimal one) by adding MTT (3-(4,5- Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide, lOpl/well) and incubating (37°C, 5% CO 2 ) them for 3 hours (until the purple-gray colored salt, is detectable). Plates were centrifuged (150g, 5min, 4°c), the supernatants discarded, and the pellet consisting of the purple-gray MTT formazan dissolved in DMSO (lOOpl, Sigma, MO, USA).
  • Optical density (OD) absorption was measured at 570nm in ELISA reader (BIO-TEK, Winooski, USA).
  • the viability of B16-F10 cells was determined by using anti-mouse CEACAM1 mAb (mCEACAMl) (provided by Dr. Bernhard Singer from the Institute of Anatomy, Essen, Germany) following the same protocol.
  • Cisplatin was first assessed (provided by Prof Dan Gibson, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem) IC50 on Mel- 14 cells. Then Mel- 14 were incubated for 72hr with a constant concentration of Cisplatin (2.5pg/ml) and increasing doses of anti-CEACAMl (0.1, 0.5, 1, 2.5, 5, lOpg/ml) and cell viability was determined by MTT as described above.
  • FC Flow Cytometry - Detection of CEACAM1 on the different cancer cell lines was performed by FC.
  • Cells (IxlO 5 cell/lOOpl/well) were resuspended in FC buffer containing PBS/0.1% bovine serum albumin (BSA) and seeded in 96-well plates, washed in the same medium, and resuspended in blocking buffer (PBS 5% Goat serum, Biological Industries, Beit Haemek, Israel) for 15min on ice. Then, cells were washed and incubated with anti-CEACAMl mAb or IgGl (2.5pg/ml) or FC buffer only for 40min on ice.
  • BSA bovine serum albumin
  • Binding assay - Micro-Scale Thermophoresis was used to establish the binding affinity between anti-CEACAMl mAb (clones 01 and 19) and CEACAM1.
  • the CEACAM1 fusion protein (provided by Prof. Ofer Mandelboim) was labeled using the monolith NT protein labeling kit RED-NHS (NanoTemper Technologies GmbH, Kunststoff, Germany) according to the company instructions.
  • Apoptosis assay - Melanoma cell apoptosis was quantified by FC using AnnexinV/PI staining (BD, San Jose, CA, USA). Mels-14 cells seeded in 6 wells plate in their medium (5xl0 5 cells/2ml/wells) were incubated overnight (ON). Anti-CEACAMl or IgGl (lOpg/ml) were then added and cells incubated for an additional 24hr. The cells were then washed with binding buffer (Thermo Fisher), stained with AnnexinV-FITC and acquired by FC in FACS calibur.
  • mice Females, 6-7 weeks old, Harlan, ENVIGO were maintained in SPF conditions. After three acclimatization days, mice were shaved and injected subcutaneously (sc) in the right flank with Mel- 14 cells (5xl0 6 /200pl cold PBS). Anti-CEACAMl or IgGl (50 or 500pg/kg in lOOpl ice cold PBS were injected intraperitoneally (ip) 30 minutes after tumor inoculation and thereafter every other day until tumors reached ⁇ 15mm 3 (according to HUJI ethical animal guidelines) and mice were consequently euthanized by isoflurane.
  • mice were weighted to detect a decrease in weight or signs of sickness.
  • tumors were excised, weighed and fixed in 4% formaldehyde and paraffin- embedded for histopathologic or immunohistochemically studies.
  • Anti CD66a and anti CEACAM1 are used herein interchangeably.
  • the recombinant immunogen combines extracellular part of the human protein and human Fc region of an immunoglobulin G carrier.
  • BALB/c mice were injected with 50 pg of the immunogen in complete Freund's adjuvant and 2 weeks later in incomplete Freund's adjuvant. After 2 weeks, the sera were screened for the antibody titer. The best responders (the serum was monitored by ELISA assay for the titer of the antibodies) were boosted with the immunogen in PBS. Three days later, spleen cells were collected, and after lysis of red blood cells, fused with SP2/0 cells.
  • the cells were seeded in 20 % RPMI 1640 medium containing hypoxanthine, aminopterine, and thymidine for hybridoma selection and screened for mAbs using ELISA.
  • Stable hybridoma cell lines were generated by fusing SP2/0 myeloma cells with spleen cells of an immunized mouse.
  • Positive outcomes were further selected to develop a product that will have several differentiating characteristics: a) high yield to reduce the antibody-production costs and enable the testing of antibodies in a number of different techniques that require purified antibodies; b) the lack of cross-reactivity with other ligands of the immune cell receptors with emphasis on other members of the CEACAM family (transfectants expressing on their plasma membrane different ligands and different protein domains were used for this purpose); c) a strong binding capacity to the native, mature human CEACAM 1 molecules expressed on the surface of live cells. Indeed, the human and mouse CEACAM1 have high level of homology and it is not easy to generate a mouse monoclonal antibody that recognizes a human homologue.
  • human CEACAM 1 is extensively glycosylated on its extracellular region.
  • CEA members who share structural units. For these reasons, it is not easy to generate an antibody that recognizes a native protein using common antigens (such as E. coli derived ones).
  • Antibodies that recognize a native human CEACAM 1 form on live cells were identified, which is a prerequisite to develop an agent that would bind and affect the human cells during the treatment.
  • CCM5.01, CCM5.18 and CCM5.19 Three anti-CEACAMl mAbs denoted CCM5.01, CCM5.18 and CCM5.19, were generated. All clones were found to be stable, having an IgGl isotype and produce large amount of antibodies (more than 1 pg/ml). As can be seen in Figure 1, the three antibodies specifically recognize CEACAM1 transfected 721.221 cells and do not recognize the parental, non-transfected cells. The three antibodies are non-blocking and do not block the binding of CEACAM 1-Ig to CEACAM 1 expressed on the cells ( Figure 2).
  • Example 2 Anti CEACAM1 antibodies reduce viability of melanoma cells in vitro
  • 1106mel cell line derived from a melanoma patient were used.
  • Human melanoma 1106mel cells were incubated with the three anti- CEACAM1 mAbs (CCM5.01, CCM5.18 and CCM5.19) or with the control mouse IgG mAb, and the effect of the antibodies on cell death in vitro was determined.
  • CCM5.01, CCM5.18 and CCM5.19 the three anti- CEACAM1 mAbs
  • the control mouse IgG mAb the effect of the antibodies on cell death in vitro was determined.
  • all three anti- CEACAM1 mAbs recognized the cells expressing CEACAM1 efficiently.
  • Around 90% CEACAM1 -mediated death is observed (Figure 5).
  • Similar results of significant death induced by CCM5.01 were obtained with two human colon cell lines HT-29 and LoVo cells ( Figure 15)..
  • mice were injected i.p. with either anti- CEACAMl, IgGl (50 and 500pg/kg), or PBS 30 minutes after tumor cells graft (s.c., day 0), and then injected every other day.
  • the results shown in Figures 8A-8C and in Table 1 indicate that the difference between tumor weight of treated and untreated mice increases in dose- dependent manner.
  • CEACAM1 is expressed on human hepatocellular carcinoma (HC4), colorectal adenocarcinoma (LOVO) and epithelial colon cancer (LS174) cell lines and its activation decreases their survival
  • CEACAM1 is expressed on tumors other than melanoma
  • FC flow cytometry
  • HC4 human hepatocellular carcinoma
  • LOVO colorectal adenocarcinoma
  • LS174 human epithelial colon
  • LOVO cell lines were exposed to anti-CEACAMl mAbs (CCM5.01 CCM5.18 and CCM5.19 at lOpg/ml), or IgGl for 72hr, and cell viability was checked by MTT. Preliminary results indicate a reduction of up to 40% in cell viability in response to the anti-CEACAMl mAbs.
  • A549 human lung carcinoma cells (IxlO 5 cell/lOOpl/well) were resuspended in FACS buffer (PBS/0.1% bovine serum albumin (BSA)) and seeded in 96-well plates, washed in the same medium, and resuspended in blocking buffer (PBS 5% Goat serum, Biological Industries, Beit Haemek, Israel) for 15min on ice. Then, cells were washed and incubated with anti- CEACAMl mAb CCM5.01 or IgGl (2.5pg/ml in FACS buffer) for 40min on ice.
  • FACS buffer PBS/0.1% bovine serum albumin (BSA)
  • BSA bovine serum albumin
  • Example 7 Additional in vivo evaluation of anti- CEACAM1 mAbs activity
  • SCID/beige mice that are deficient for T, B and NK cells and therefore accept human tumor xenografts
  • various CEACAM1 -positive tumors such as melanoma, lung, colorectal, and bladder cancer.
  • the mice are injected with the anti- CEACAM1 mAbs of the invention and with a negative control antibody.
  • Example 8 Anti-CEACAMl mAbs support the anti-cancer activity of immune cells expressing CEACAM1 in vivo
  • B16-F10 murine melanoma cells were injected subcutaneously in the right flank of 6-7 weeks male transgenic mice expressing human but not murine CEACAM1 (hCEACAMl+/+ x msCEACAMl-/-).
  • the mice were treated immediately after cell inoculation and then 3 times a week with intraperitoneal injections of either anti-human CEACAM1 or anti-murine CEACAM1 mAbs or with their isotype control IgGl (lOOpg/mice).
  • the tumor growth was monitored by measuring its size using a caliper for 16 days until reaching the size of 15mm 3 .
  • mice were then sacrificed, and tumor weight was measured. Spleen from mice bearing tumors were extracted, washed in PBS and meshed through 70pm filter. Then, total cells number were counted and stained using standard flow cytometry staining protocol. T cells were stained using FITC conjugated anti-CD3 monoclonal antibody.
  • Figures 10B and 10C represent a decrease in tumor growth and tumor weight, respectively, by anti-human CEACAM1 mAbs, indicating that these antibodies may support the immune cells to fight against cancer.
  • spleenocytes analysis by flow cytometry (Figure 10D) showed an increase in CD3 + cells, demonstrating that anti-human CEACAM1 mAb increase T cells number.
  • anti-human CEACAM1 mAb also act on the immune level by increasing the immune cell number and contributing to a stronger anti-tumor immunity
  • CEACAM1 extracellular domain contains immunoglobulin variable-region-like (IgV- like) domain at the N terminus of the protein and 1 to 3 immunoglobulin constant-region-type- 2-like (IgC2-like) domains.
  • IgV- like immunoglobulin variable-region-like domain at the N terminus of the protein
  • IgC2-like immunoglobulin constant-region-type- 2-like domains.
  • the mAbs were incubated on ELISA plate coated with CEACAM1 bearing (CCl-Fc) or lacking (CCldN-Fc) the N-terminal domain, followed by incubation with HRP. Binding was detected by plate reader at OD450nm.
  • Example 10 Staining of CEACAM1 on human eosinophils
  • CEACAM1 is upregulated in viral infection
  • its expression on eosinophils from healthy donor and 4 Covid- 19 patients was determined by using standard flowcytometry staining protocol. Eosinophils were isolated using anti-CCR3-APC antibody and stained by the anti-CEACAMl mAb CCM5.01 followed by FITC-anti-mouse IgG.
  • Example 12 CCM5.01 and CCM5.19 mAbs do not bind to the N domain of human CEACAM1.
  • Example 13 CCM5.01 and CCM5.19 mAbs bind to human CEACAM1, CEACAM5 and CEACAM8.
  • Antibodies CCM5.01, CCM5.19 and respective positive control antibodies were incubated with CHO, CHO-mouse CEACAM1, CHO-human CEACAM1, CHO-human CEACAM3, CHO-human CEACAM5, CHO-human CEACAM6, CHO-human CEACAM7, CHO-human CEACAM8 transfectants. After washing, FITC-labeled secondary goat anti mouse antibody was applied. Cell surface binding was analyzed utilizing a FACScalibur flow cytometer (Becton Dickinson) and analyzed by CellQuestPro (Becton Dickinson). Data shown represent the median values of one out of three different, representative experiments.
  • composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2, Liu X.et al, [published online ahead of print, 2020 Feb 26], J Me d Virol. 202();l().1002/jmv.25726. doi:10.1002/jmv.25726.
  • N-terminal Domain of the Murine Coronavirus Receptor CEACAM1 Is responsible for Fusogenic Activation and Conformational Changes of the Spike Protein HS Miura et al. 2004J Virol 78 :216-223.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux qui reconnaissent la protéine CEACAM1 avec une affinité et une spécificité élevées. Les anticorps reconnaissent CEACAM1 avec une activité de non-blocage. La présente invention concerne en outre des compositions pharmaceutiques comprenant les anticorps et des procédés pour leur utilisation dans l'immunothérapie anticancéreuse, dans la prévention et le traitement d'une infection virale et dans le diagnostic.
PCT/IL2022/051305 2021-12-12 2022-12-11 Anticorps spécifiques de ceacam1 WO2023105528A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163288609P 2021-12-12 2021-12-12
US63/288,609 2021-12-12

Publications (1)

Publication Number Publication Date
WO2023105528A1 true WO2023105528A1 (fr) 2023-06-15

Family

ID=84887864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2022/051305 WO2023105528A1 (fr) 2021-12-12 2022-12-11 Anticorps spécifiques de ceacam1

Country Status (1)

Country Link
WO (1) WO2023105528A1 (fr)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1993015210A1 (fr) 1992-01-23 1993-08-05 Merck Patent Gmbh Proteines fusionnees monomeres et dimeres a fragments d'anticorps
WO1996013583A2 (fr) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Hetero-association ciblee de proteines recombinees et de complexes fonctionnels
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1996037621A2 (fr) 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Proteines multimeres
WO1997002671A2 (fr) 1995-06-30 1997-01-23 Scientific Atlanta, Inc. Demodulateur de signaux de bande de base a plusieurs voies telephoniques destine a un systeme de telecommunications a large bande
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1999052552A1 (fr) 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. Compositions pour recepteurs inhibiteurs des lymphocytes t et utilisation de telles compositions
US8999554B2 (en) 2011-12-27 2015-04-07 Lg Chem, Ltd. Lithium secondary battery and preparation thereof
WO2015166484A1 (fr) 2014-04-27 2015-11-05 Ccam Therapeutics Ltd. Anticorps humanisés dirigés contre ceacam1
WO2019023410A1 (fr) * 2017-07-28 2019-01-31 Phanes Therapeutics, Inc. Anticorps anti-tim-1 et leurs utilisations
WO2021059075A1 (fr) * 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anticorps anti-ceacam et leurs utilisations

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
WO1993015210A1 (fr) 1992-01-23 1993-08-05 Merck Patent Gmbh Proteines fusionnees monomeres et dimeres a fragments d'anticorps
WO1996013583A2 (fr) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Hetero-association ciblee de proteines recombinees et de complexes fonctionnels
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1996037621A2 (fr) 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Proteines multimeres
WO1997002671A2 (fr) 1995-06-30 1997-01-23 Scientific Atlanta, Inc. Demodulateur de signaux de bande de base a plusieurs voies telephoniques destine a un systeme de telecommunications a large bande
WO1999052552A1 (fr) 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. Compositions pour recepteurs inhibiteurs des lymphocytes t et utilisation de telles compositions
US8999554B2 (en) 2011-12-27 2015-04-07 Lg Chem, Ltd. Lithium secondary battery and preparation thereof
WO2015166484A1 (fr) 2014-04-27 2015-11-05 Ccam Therapeutics Ltd. Anticorps humanisés dirigés contre ceacam1
WO2019023410A1 (fr) * 2017-07-28 2019-01-31 Phanes Therapeutics, Inc. Anticorps anti-tim-1 et leurs utilisations
WO2021059075A1 (fr) * 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anticorps anti-ceacam et leurs utilisations

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
"SwissProt", Database accession no. P13688
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
FARAZ A. ET AL.: "Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies Syed", VIRUSES, vol. 12, 2020, pages 254
GRALINSKI LEMENACHERY VD: "Return of the Coronavirus: 2019-nCoV", VIRUSES, vol. 12, no. 2, 24 January 2020 (2020-01-24), pages E135
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HS MIURA ET AL.: "N-terminal Domain of the Murine Coronavirus Receptor CEACAM1 Is Responsible for Fusogenic Activation and Conformational Changes of the Spike Protein", J VIROL, vol. 78, 2004, pages 216 - 223
HUSTON ET AL., PROC. NATL. ACAD. SCI. (USA, vol. 85, 1988, pages 5879 - 5883
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 7
KRUEGER D.K.: "Variations in Disparate Regions of the Murine Coronavirus Spike Protein Impact the Initiation of Membrane Fusion", J.VIROL., vol. 75, 2001, pages 2792 - 2802
LEFRANC M-P ET AL., DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77
LETKO MMUNSTER V: "Functional assessment of cell entry and receptor usage for lineage B (3 coronaviruses, including 2019-nCoV", BIORXIV 2020.01.22.915660
LI F: "Receptor recognition mechanisms of coronaviruses: a decade of structural studies", J VIROL, vol. 89, 2015, pages 1954 - 1964, XP055809784, DOI: 10.1128/JVI.02615-14
LI FLI WFARZAN MHARRISON SC: "Structure of SARS coronavirus spike receptor-binding domain complexed with receptor", SCIENCE, vol. 309, no. 5742, 16 September 2005 (2005-09-16), pages 1864 - 8, XP002439742, DOI: 10.1126/science.1116480
LIU X. ET AL.: "Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2", J MED VIROL., 2020
LU RWANG YWANG WNIE KZHAO YSU JDENG YZHOU WLI YWANG H: "Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) from the First Imported MERS-CoV Case in China", GENOME ANNOUNC, vol. 3, no. 4, 13 August 2015 (2015-08-13), pages e00818 - 15
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MESEL-LEMOINE M ET AL.: "A Human Coronavirus Responsible for the Common Cold Massively Kills Dendritic Cells but Not Monocytes", J. VIROL., vol. 86, 2012, pages 7577 - 7587
MESEL-LEMOINE MMILLET JVIDALAIN POLAW HVABRET ALORIN VESCRIOU NALBERT MLNAL BTANGY F: "A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes", J VIROL, vol. 86, no. 14, 2 May 2012 (2012-05-02), pages 7577 - 87
MORALES ET AL., J. IMMUNOL., vol. 163, 1999, pages 1363 - 1370
MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
PENG ZSHI Z-L.: "Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin", BIORXIV 2020.01.22.914952, 2020
SIMMONS GGOSALIA DNRENNEKAMP AJREEVES JDDIAMOND SLBATES P: "Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry", PROC NATL ACAD SCI U S A., vol. 102, no. 33, 4 August 2005 (2005-08-04), pages 11876 - 81, XP055809747, DOI: 10.1073/pnas.0505577102
SONG WGUI MWANG XXIANG Y: "Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2", PLOS PATHOG, vol. 14, no. 8, 13 August 2018 (2018-08-13), pages e1007236, XP055815677, DOI: 10.1371/journal.ppat.1007236
TAN K ET AL.: "Crystal structure of murine sCEACAMla [1, 4]: a coronavirus receptor in the CEA Family", EMBO J, vol. 21, 2002, pages 2076 - 2086
TUSELL S.M. ET AL.: "Mutational Analysis of Aminopeptidase N, a Receptor for Several Group 1 Coronaviruses, Identifies Key Determinants of Viral Host Range", J VIROL, vol. 81, 2007, pages 1261 - 1273, XP055447190, DOI: 10.1128/JVI.01510-06
VITENSHTEIN ET AL.: "CEACAM1-Mediated Inhibition of Virus Production", CELL REPORTS, vol. 15, 2016, pages 2331 - 2339, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/j.celrep.2016.05.036>
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WATT ET AL.: "Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site", BLOOD, vol. 98, 2001, pages 1469 - 1479, XP002229281, DOI: 10.1182/blood.V98.5.1469
WU T.TKABAT E.A., J EXP MED, vol. 132, 1970, pages 211 - 50
YU ZHAOZIXIAN ZHAOYUJIA WANGYUEQING ZHOUYU MAWEI ZUO: "Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov", BIORXIV 2020.01.26.919985
ZAFFRAN ET AL., CANCER GENE THERAPY, vol. 29, 2022, pages 1676 - 1685
ZAFFRAN ILAN ET AL: "Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells", CANCER GENE THERAPY, vol. 29, no. 11, 9 June 2022 (2022-06-09), New York, pages 1676 - 1685, XP093026815, ISSN: 0929-1903, Retrieved from the Internet <URL:https://www.nature.com/articles/s41417-022-00486-x> DOI: 10.1038/s41417-022-00486-x *
ZAPATA ET AL., PROTEIN ENG., vol. 8, 1995, pages 1057 - 1062
ZHOU LSUN YLAN TWU RCHEN JWU ZXIE QZHANG XMA J.: "Retrospective detection and phylogenetic analysis of swine acute diarrhoea syndrome coronavirus in pigs in southern China", TRANSBOUND EMERG DIS, vol. 66, no. 2, 9 January 2019 (2019-01-09), pages 687 - 695
ZHOU, P. ET AL.: "A pneumonia outbreak associated with a new coronavirus of probable bat origin", NATURE DOI.ORG/10.1038/S41586-020-2012-7, 2020

Similar Documents

Publication Publication Date Title
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
US12077583B2 (en) Antibodies specific to human NECTIN4
EP3344658B1 (fr) Anticoprs anti tigit (human t-cell immunoglobulin and itim domain)
KR102454460B1 (ko) 암 치료를 위한 항-fam19a5 항체의 용도
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
US20220112283A1 (en) Antibodies specific to human nectin-2
US20240270840A1 (en) Antibodies against cd112r and uses thereof
WO2023105528A1 (fr) Anticorps spécifiques de ceacam1
US12121579B2 (en) Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22839510

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE